You are a subscriber
If you are not already a subscriber,
Choose a subscription offer and create your account to read all content on MediapartCreate your account
Sanofi has announced that Kevzara, a drug originally developed with US pharma firm Regeneron for treating arthritis, has failed Phase 3 tests of its effectiveness in treating severe cases of Covid-19 and which involved 420 patients in several countries.
Reading articles is for subscribers only. Subscribe now.